OnKure, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Phase 1
Recruiting
- Conditions
- Advanced CancerBreast Cancer
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06239467
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸University of California San Diego UCSD, La Jolla, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Phase 1
Completed
- Conditions
- RAS MutationMelanomaNRAS Gene Mutation
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05340621
- Locations
- 🇺🇸
CTCA Chicago, part of City of Hope, Zion, Illinois, United States
🇺🇸CTCA Phoenix, part of City of Hope, Phoenix, Arizona, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
A Study of OKI-179 in Patients With Solid Tumors
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03931681
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath